BRIEF-Paratek Pharmaceuticals Announces Positive Top-Line Data From Phase 2B Study Of Oral Omadacycline

Reuters11-08

Nov 8 (Reuters) -

Paratek Pharmaceuticals:

* PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STUDY OF ORAL OMADACYCLINE $(OMC)$ IN NONTUBERCULOUS MYCOBACTERIAL $(NTM.AU)$ ABSCESSUS PULMONARY DISEASE

* PARATEK: TREND FAVORING OMADACYCLINE CONSISTENTLY OBSERVED ACROSS TOP LINE PRIMARY & SECONDARY ENDPOINTS

* PARATEK: OMADACYCLINE SAFE AND WELL-TOLERATED WITH NO NEW OR UNEXPECTED SAFETY SIGNALS

Source text:

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481106877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481106877","market":"us","top_or_hot":-1,"title":"BRIEF-Paratek Pharmaceuticals Announces Positive Top-Line Data From Phase 2B Study Of Oral Omadacycline","media":"Reuters","content":"<html><body><p>Nov 8 (Reuters) - </p><p>   Paratek Pharmaceuticals:</p><p>   * PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STUDY OF ORAL OMADACYCLINE <a href=\"https://laohu8.com/S/OMC\">$(OMC)$</a> IN NONTUBERCULOUS MYCOBACTERIAL <a href=\"https://laohu8.com/S/NTM.AU\">$(NTM.AU)$</a> ABSCESSUS PULMONARY DISEASE</p><p>   * PARATEK: TREND FAVORING OMADACYCLINE CONSISTENTLY OBSERVED ACROSS TOP LINE PRIMARY &amp; SECONDARY ENDPOINTS</p><p>   * PARATEK: OMADACYCLINE SAFE AND WELL-TOLERATED WITH NO NEW OR UNEXPECTED SAFETY SIGNALS</p><p>Source text:   </p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Paratek Pharmaceuticals Announces Positive Top-Line Data From Phase 2B Study Of Oral Omadacycline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Paratek Pharmaceuticals Announces Positive Top-Line Data From Phase 2B Study Of Oral Omadacycline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 8 (Reuters) -    Paratek Pharmaceuticals:   * PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STUDY OF ORAL OMADACYCLINE $(OMC)$ IN NONTUBERCULOUS MYCOBACTERIAL $(NTM.AU)$ ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0742537680.HKD","symbol_name":"FIDELITY GLOBAL DIVIDEND \"A \" (HKD) INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481106877","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481106877","pubTimestamp":1731075147,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 8  -    Paratek Pharmaceuticals:   * PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STUDY OF ORAL OMADACYCLINE  IN NONTUBERCULOUS MYCOBACTERIAL  ABSCESSUS PULMONARY DISEASE   * PARATEK: TREND FAVORING OMADACYCLINE CONSISTENTLY OBSERVED ACROSS TOP LINE PRIMARY & SECONDARY ENDPOINTS   * PARATEK: OMADACYCLINE SAFE AND WELL-TOLERATED WITH NO NEW OR UNEXPECTED SAFETY SIGNALSSource text:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0742537680.HKD":"FIDELITY GLOBAL DIVIDEND \"A \" (HKD) INC","LU0772969993.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) ACC","LU1481011671.HKD":"FIDELITY GLOBAL DIVIDEND \"A\" (HKDHDG) INC","BK4009":"广告","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4585":"ETF&股票定投概念","PRTK":"Paratek Pharmaceuticals Inc.","LU0731783048.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC MONTHLY (G)","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","LU1481011911.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USDHDG) INC","BK4588":"碎股","LU1509826696.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC B","BK4007":"制药","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","OMC":"宏盟集团"},"translate_title":"简介-Paratek Pharmaceuticals宣布口服omadacycline 2b期研究的积极顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMC":1,"PRTK":1},"content_text":"Nov 8 (Reuters) -    Paratek Pharmaceuticals:   * PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STUDY OF ORAL OMADACYCLINE $(OMC)$ IN NONTUBERCULOUS MYCOBACTERIAL $(NTM.AU)$ ABSCESSUS PULMONARY DISEASE   * PARATEK: TREND FAVORING OMADACYCLINE CONSISTENTLY OBSERVED ACROSS TOP LINE PRIMARY & SECONDARY ENDPOINTS   * PARATEK: OMADACYCLINE SAFE AND WELL-TOLERATED WITH NO NEW OR UNEXPECTED SAFETY SIGNALSSource text:    (Reuters.Briefs@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481106877"}